Skip to main navigation Skip to search Skip to main content

Comparison of characteristics and outcomes of bleeding patients treated with Andexanet alfa and 4-factor PCC (4FPCC): A Feasibility Study

Project: Research

Project Details

StatusFinished
Effective start/end date05/1/21 → 04/30/24

Funding

  • Alexion Pharmaceuticals Incorporated: $250,000.00